Welcome to our dedicated page for Adocia news (Ticker: ADOCY), a resource for investors and traders seeking the latest updates and insights on Adocia stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adocia's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adocia's position in the market.
Adocia, based in
- March 15: 2022 financial statements
- April 25: Q1 2023 revenue
- July 25: Q2 2023 revenue
- September 18: mid-year financial statements
- October 25: Q3 2023 revenue
Adocia announced positive results for BioChaperone Lispro in a Phase 1 study, confirming its accelerated absorption and efficacy compared to traditional insulin lispro. The ongoing Phase 3 studies are the last steps before submitting a marketing authorization application to Chinese authorities. BioChaperone Lispro, expected to be the first ultra-rapid insulin marketed in China by a domestic company, aims to improve the lives of over 20 million daily insulin users in a market worth over $5 billion.
Adocia (Euronext: ADOC) announces its participation in several investor events in January 2023, focusing on diabetes and metabolic disease treatments. Events include the ODDO BHF Forum (Jan 9-10, virtual) and the JPM 2023 Healthcare Meeting (Jan 9-12, San Francisco). Additionally, Olivier Soula, Deputy CEO, will present at the Biotech Showcase (Jan 9-11, San Francisco) on Jan 10, discussing innovations in diabetes and the company's clinical programs. Adocia specializes in therapeutic solutions for metabolic diseases.
Adocia announced a EUR 6 million financing operation, enhancing its cash position to EUR 20.7 million. This funding will support the development of promising diabetes treatments, M1Pram and AdoShell Islets. The company anticipates significant revenue from a partnership with Tonghua Dongbao, with potential milestones totaling USD 80 million. Notable progress includes M1Pram's weight loss results in Type 1 diabetes patients and AdoShell Islets achieving insulin independence in diabetic rats. Adocia aims to secure at least one license agreement for these projects to bolster financial stability.
Adocia reported a strong financial performance for Q3 2022, achieving a cash position of
Adocia has announced positive results from its Phase 2 study of M1Pram for obese patients with type 1 diabetes. Patients experienced an average weight loss of 5.5 kg at 16 weeks, significantly more than those on Humalog®. M1Pram also provided comparable glycemic control, maintaining HbA1c levels and Time-In-Range. The study indicated better appetite control in 82.4% of M1Pram users. Notably, M1Pram could reduce daily prandial insulin doses by 21%, marking it as a potential treatment option for obesity in type 1 diabetes.
Adocia, a clinical-stage biopharmaceutical company, will participate in key investor events in Paris, including Investor Access on October 6-7, 2022, and Biotech Agora on November 3, 2022. The management will present updates on clinical advancements in programs like BioChaperone Lispro and discuss innovative technologies AdoShell and AdOral. Based in Lyon, Adocia specializes in diabetes and metabolic disease treatments and holds over 25 patents related to its drug candidates.
FAQ
What is the market cap of Adocia (ADOCY)?
